
Cat. #162290
SBP-SUMO2 expressing H1299 cell line
Cat. #: 162290
Organism: Human
Tissue: Lung
Disease: Cancer
Model: Transgenic
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Petr Muller
Institute: Masaryk Memorial Cancer Institute
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: SBP-SUMO2 expressing H1299 cell line
- Cancer type: Lung cancer
- Parental cell: H1299
- Clone: H1299-947
- Organism: Human
- Gender: Male
- Tissue: Lung
- Donor: 43 years old, white
- Disease: Cancer
- Morphology: Epithelial
- Growth properties: Adherent
- Model: Transgenic
- Model description: Expression of small ubiquitin-related modifier 2 (SUMO2) with a streptavidin binding protein (SPB) tag
- Crispr: No
- Conditional: No
- Description: H1299 cell line derivative expressing the small ubiquitin-related modifier 2 (SUMO2) with a streptavidin binding protein (SPB) tag
- Application: Cell culture
- Biosafety level: BSL-2
Target Details
- Target: SUMO2
- Target background: SUMO2 binds to proteins as part of the post-translational modification and is involved in a variety of cellular processes, such as nuclear transport, transcriptional regulation, apoptosis, and protein stability
Applications
- Application: Cell culture
Handling
- Format: Frozen
- Atmosphere: humidified CO2 atmosphere
- Storage conditions: Liquid Nitrogen
- Cultured in antibiotics: Yes, penicillin/streptomycin
References
- Unpublished
![Anti-CAR Whitlow Linker [1C3C3]](https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-300x322.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-280x300.jpg 280w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-954x1024.jpg 954w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025-768x824.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-6-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 1193w)

![Anti-CAR Whitlow Linker [1B4A1]](https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-300x396.jpg 300w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-227x300.jpg 227w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-776x1024.jpg 776w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025-768x1013.jpg 768w, https://cancertools.org/wp-content/uploads/Figure-5-Kimble-et-al.-J-Immunother-Cancer-2025.jpg 970w)



